2025 Q2 -tulosraportti
183 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
5 899
Myynti
Määrä
20 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 452 | - | - | ||
| 3 000 | - | - | ||
| 7 575 | - | - | ||
| 10 000 | - | - | ||
| 10 000 | - | - |
Ylin
2,9VWAP
Alin
2,31VaihtoMäärä
73,1 27 522 909
VWAP
Ylin
2,9Alin
2,31VaihtoMäärä
73,1 27 522 909
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenFrom today's call: “Milestones going forward: We have broad activities. The funding allows us to accelerate activities to do more studies in parallel, and this means that we will have exciting readouts coming up. We showed you already the circVec 3 and 4 data in heart and eye [i.e., today]. We will have more of that … the data package in heart is very expansive now and we are doing the same in eye so we will understand more precisely how it works there. And then we expect to release CNS data later in the second quarter. And next step is to move to disease constructs. What we are doing now is what we call reporters, these luciferase genes that light up that are good for experimental purpose. The next step is to use actual disease genes. And that is work that is ongoing, being tested in vitro at the moment and we're going in vivo soon. Again we expect to present data in Q2. The T-cell delivery for in vivo CAR is also actively ongoing and that should deliver data in Q2. So I think all of these readouts here we expect to have **before the warrant exercise period in June**.” (my emphasis)
·2 t sittenThis will happen one after another throughout the spring with announcements. He also saw collaboration agreements coming. Clearly they already have new R&D collaborations in place. Already on March 18-19 they will be at LSX RNA Leaders, so it's possible something might come then.- ·4 t sitten · MuokattuOver 73 mill in revenue today and over 50 mill yesterday.
- ·4 t sittenThere is little doubt about what the company is planning through a preferential issue, warrants, and the timing of the GF and subscription period in relation to ASGCT 2026. The share price will go up, There is a lot of gunpowder in the barrel here. That more partnerships will come before April 1...? Yes, as well as more updates on technology. Then the rumor mill starts asking itself... how long does Big Pharma dare to stay out of this unique technology from Circio? Sleep well - dream big.
·7 t sittenAre we talking 30% up tomorrow?
·4 t sittenWould be fun, but I'd be very surprised if that were to happen. I'd be happy if we stay where we are now for a while, around the 2.4-2.8 area. So that the share finds its level, then throughout the spring there will certainly be more news with which the price will take new steps.
·7 t sittenWhat would a fair price be if another company were to buy circio. Are we talking 10-15 kroner. Per share
·1 t sittenSo you mean that it can end up in 15 Billion in acquisitions? How did you arrive at that and how long do you think it will take?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
183 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenFrom today's call: “Milestones going forward: We have broad activities. The funding allows us to accelerate activities to do more studies in parallel, and this means that we will have exciting readouts coming up. We showed you already the circVec 3 and 4 data in heart and eye [i.e., today]. We will have more of that … the data package in heart is very expansive now and we are doing the same in eye so we will understand more precisely how it works there. And then we expect to release CNS data later in the second quarter. And next step is to move to disease constructs. What we are doing now is what we call reporters, these luciferase genes that light up that are good for experimental purpose. The next step is to use actual disease genes. And that is work that is ongoing, being tested in vitro at the moment and we're going in vivo soon. Again we expect to present data in Q2. The T-cell delivery for in vivo CAR is also actively ongoing and that should deliver data in Q2. So I think all of these readouts here we expect to have **before the warrant exercise period in June**.” (my emphasis)·2 t sittenThis will happen one after another throughout the spring with announcements. He also saw collaboration agreements coming. Clearly they already have new R&D collaborations in place. Already on March 18-19 they will be at LSX RNA Leaders, so it's possible something might come then.
- ·4 t sitten · MuokattuOver 73 mill in revenue today and over 50 mill yesterday.
- ·4 t sittenThere is little doubt about what the company is planning through a preferential issue, warrants, and the timing of the GF and subscription period in relation to ASGCT 2026. The share price will go up, There is a lot of gunpowder in the barrel here. That more partnerships will come before April 1...? Yes, as well as more updates on technology. Then the rumor mill starts asking itself... how long does Big Pharma dare to stay out of this unique technology from Circio? Sleep well - dream big.
- ·7 t sittenAre we talking 30% up tomorrow?·4 t sittenWould be fun, but I'd be very surprised if that were to happen. I'd be happy if we stay where we are now for a while, around the 2.4-2.8 area. So that the share finds its level, then throughout the spring there will certainly be more news with which the price will take new steps.
- ·7 t sittenWhat would a fair price be if another company were to buy circio. Are we talking 10-15 kroner. Per share·1 t sittenSo you mean that it can end up in 15 Billion in acquisitions? How did you arrive at that and how long do you think it will take?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
5 899
Myynti
Määrä
20 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 452 | - | - | ||
| 3 000 | - | - | ||
| 7 575 | - | - | ||
| 10 000 | - | - | ||
| 10 000 | - | - |
Ylin
2,9VWAP
Alin
2,31VaihtoMäärä
73,1 27 522 909
VWAP
Ylin
2,9Alin
2,31VaihtoMäärä
73,1 27 522 909
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
183 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenFrom today's call: “Milestones going forward: We have broad activities. The funding allows us to accelerate activities to do more studies in parallel, and this means that we will have exciting readouts coming up. We showed you already the circVec 3 and 4 data in heart and eye [i.e., today]. We will have more of that … the data package in heart is very expansive now and we are doing the same in eye so we will understand more precisely how it works there. And then we expect to release CNS data later in the second quarter. And next step is to move to disease constructs. What we are doing now is what we call reporters, these luciferase genes that light up that are good for experimental purpose. The next step is to use actual disease genes. And that is work that is ongoing, being tested in vitro at the moment and we're going in vivo soon. Again we expect to present data in Q2. The T-cell delivery for in vivo CAR is also actively ongoing and that should deliver data in Q2. So I think all of these readouts here we expect to have **before the warrant exercise period in June**.” (my emphasis)·2 t sittenThis will happen one after another throughout the spring with announcements. He also saw collaboration agreements coming. Clearly they already have new R&D collaborations in place. Already on March 18-19 they will be at LSX RNA Leaders, so it's possible something might come then.
- ·4 t sitten · MuokattuOver 73 mill in revenue today and over 50 mill yesterday.
- ·4 t sittenThere is little doubt about what the company is planning through a preferential issue, warrants, and the timing of the GF and subscription period in relation to ASGCT 2026. The share price will go up, There is a lot of gunpowder in the barrel here. That more partnerships will come before April 1...? Yes, as well as more updates on technology. Then the rumor mill starts asking itself... how long does Big Pharma dare to stay out of this unique technology from Circio? Sleep well - dream big.
- ·7 t sittenAre we talking 30% up tomorrow?·4 t sittenWould be fun, but I'd be very surprised if that were to happen. I'd be happy if we stay where we are now for a while, around the 2.4-2.8 area. So that the share finds its level, then throughout the spring there will certainly be more news with which the price will take new steps.
- ·7 t sittenWhat would a fair price be if another company were to buy circio. Are we talking 10-15 kroner. Per share·1 t sittenSo you mean that it can end up in 15 Billion in acquisitions? How did you arrive at that and how long do you think it will take?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
5 899
Myynti
Määrä
20 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 452 | - | - | ||
| 3 000 | - | - | ||
| 7 575 | - | - | ||
| 10 000 | - | - | ||
| 10 000 | - | - |
Ylin
2,9VWAP
Alin
2,31VaihtoMäärä
73,1 27 522 909
VWAP
Ylin
2,9Alin
2,31VaihtoMäärä
73,1 27 522 909
Välittäjätilasto
Dataa ei löytynyt